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ABSTRACT
Objective: This study was designed to analyze the role of piperine in modulating P-glycoprotein mRNA expression when added in combination with 
tamoxifen to breast cancer cells in culture.
Methods: MCF-7 breast cancer cells were treated with 1 µM tamoxifen with or without piperine (12.5, 25, or 50 µM) or verapamil 50 µM (P-glycoprotein 
inhibitor positive control) for up to 12 days. We assessed the cell viability and isolated total RNA from them. We quantified P-glycoprotein expressions 
using quantitative reverse transcription polymerase chain reaction.
Results: Administration of various doses of piperine decreased MCF-7 breast cancer cell viability. Piperine, when given in combination with tamoxifen, 
decreased the expression of P-glycoprotein mRNA in cells compared with the expression in cells treated with tamoxifen only. The effects were shown 
to be dose dependent.
Conclusion: Piperine prevents the development of breast cancer cell tamoxifen resistance, probably through its inhibition of P-glycoprotein expression.
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INTRODUCTION
Breast cancer continues to be a global burden for women as the most 
common cancer and the leading cause of cancer deaths in women [1]. 
Premenopausal women with estrogen-positive type of breast cancer 
can benefit from tamoxifen treatment [2]. However, studies have shown 
that the response rates to tamoxifen are approximately 17–33% with 
times to progression between 5 and 8.3 months [3,4]. The long-term use 
of tamoxifen has been shown to induce decreased cancer cell sensitivity 
to the drug; one mechanism of resistance is the increased expression of 
drug efflux transporters such as P-glycoprotein [5].
The P-glycoprotein efflux transporter is part of the superfamily of ATP-
binding cassette transporters. P-glycoprotein mediates resistance to 
various anticancer drugs, such as tamoxifen, vincristine, vinblastine, 
and paclitaxel. The long-term use of anticancer drugs can trigger 
increased P-glycoprotein expression through the activation of pregnane 
X receptor (PXR) so that the anticancer drugs cannot attain effective 
concentrations inside the cells, leading to drug treatment failure [6].
Various efforts have been devised to overcome this resistance; one of 
them is to provide P-glycoprotein inhibitors in addition to chemotherapy. 
Three generations (1, 2, and 3) of P-glycoprotein inhibitors have been 
developed. However, the preclinical trials done on these drugs have not 
been satisfactory. The clinical applications for P-glycoprotein inhibitors 
are still limited and more research is needed to ensure the deployment 
of a safe and effective P-glycoprotein inhibitor [7,8].
One alternative source of P-glycoprotein modulators is found in plants. 
Some drugs of natural origin have beneficial effects, such as anticancer 
effects and also as inhibitors of P-glycoprotein [9]. Piperine is one of 
the known natural isolates inhibiting P-glycoprotein. It is an alkaloid 
found in Piper longum L. and Piper nigrum L. plants, better known as 
black pepper [10]. Piperine helps to reduce inflammation, improves 
digestive function, reduces pain and asthma, increases the production 
of serotonin, reduces gastric ulceration, and displays antitumor 
activity [11]; therefore, it is expected to provide dual benefits for the 
management of breast cancer.
In this study, we aimed to analyze the role of piperine in modulating 




We conducted an in vitro study using MCF-7 breast cancer cells. 
The breast cancer cell line MCF-7 was obtained from the Makmal 
Laboratory (FKUI, Indonesia). Tamoxifen was obtained from Santa 
Cruz (USA). Piperine, verapamil, and dimethylsulfoxide (DMSO) were 
obtained from Sigma-Aldrich. Dulbecco’s minimal essential medium 
(DMEM), triple express, and fetal bovine serum (FBS) were obtained 
from Gibco (Singapore). The Total RNA Mini Kit was obtained from 
Geneaid (Taiwan). Primers used for quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) were purchased from 1st base 
(Singapore). The KAPA SYBR fast one-step RT-PCR Kit Bio-Rad iCycler 
was obtained from KAPA Biosystems (USA). All other chemicals used in 
this study were of the highest commercially available purity.
Cell culture
MCF-7 cells were cultured on DMEM medium supplemented with 10% 
FBS, penicillin 100 IU/mL, streptomycin 100 µg/mL, and fungizone 
2.5 µg/mL at 37 °C and 5% CO2. We subcultured the cells at about 80–
90% confluency and placed them onto 6-well plates for drug treatments.
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Preparation of drugs
Tamoxifen, verapamil, and piperine were dissolved in DMSO and then 
diluted into DMEM at the desired concentrations. The final DMSO 
concentrations were <0.001%. We used a concentration of tamoxifen of 
1 µM, based on a publication using MCF-7 cells [12].
Drug treatment
We plated 100,000 MCF-7 cells onto a 6-well plate and incubated them 
for 24 h before the drug treatment. Tamoxifen (1 µM) and piperine 
(12.5, 25 and 50 µM) were applied together in the exchange media on 
days 1, 4, 6, 9, and 12. We used DMSO (0.001%) for our negative control 
and verapamil (50 µM) for the positive control with a P-glycoprotein 
inhibitor. At the end of each time point, we harvested the cells using 
triple express and counted them using a hemocytometer. Next, we 
performed total RNA extractions according to the manufacturers’ 
procedure.
qRT-PCR
Quantitative RT-PCRs were done on a Bio-Rad iCycler machine 
using the KAPA SYBR Fast one-step qRT-PCR kit (KAPA, USA). We 
used primer sequences to amplify the P-glycoprotein gene and 
the GAPDH gene as a reference. The primer sequences used were: 
GAPDH Fwd: 5′-GTTGCTGTAGCCAAATTCGTTGT-3′, GAPDH Rev: 
5′-GGTGGTCTCCTCTGACTTCAACA-3′, P-glycoprotein Fwd: 5′-AATAG 
ATGCC TTTCTGTGCAAG-3′, and P-glycoprotein Rev: 5′-AAAGCGACT 
GAATGTTCAGTGG-3′. Samples were prepared by mixing 200 nM of each 
primer, 7.5 µL KAPA SYBR Fast qPCR Master Mix Green, 0.4 mL KAPA RT 
Mix (50X), 0.4 mL dUTP, 275 ng RNA Template, and RNase-free water to 
15 µL. The samples were incubated in the qRT-PCR machine under the 
following conditions: 5 min at 42°C for cDNA synthesis, 5 min at 95°C 
for reverse transcriptase inactivation, and 35 cycles consisting of 3 s at 
95°C for template denaturation and 1 min at 64°C for primer annealing, 
plus 30 s for the extension phase. After that, a final elongation for 
5 min and 30 s was added to the cycle 81 times for obtaining melting 
curves. The Thermal Cycler software calculated the threshold value (Ct) 
automatically. The data were then processed according to the Ct Livak 
method [13].
RESULTS
Treatment with tamoxifen (1 µM) suppressed the viability of MCF-
7 cells for up to 4 days. However, after 6 days of treatment, we found 
that the cell growth increased compared with that in the control (Fig. 1).
The analysis of P-glycoprotein mRNA expressions after treatment of 
MCF-7 cells with tamoxifen (1 µM) showed a similar trend to that in the 
cell viability curve, increasing in a time-dependent manner starting on 
day 6 (Fig. 2).
The concomitant treatment with tamoxifen (1 µM) and piperine (12.5, 
25, or 50 µM) reduced the number of viable MCF-7 cells in dose- and 
time-dependent manners (Fig. 3).
We found decreased P-glycoprotein mRNA expressions after the 
concomitant treatment of MCF-7 cells with tamoxifen (1 µM) and 
either piperine (12.5, 25, and 50 µM) or verapamil (50 µM) (Fig. 4). 
The greatest decrease in P-glycoprotein expression was observed with 
50 µM of verapamil.
DISCUSSION
We conducted this study to investigate the role of piperine, when given 
in combination with tamoxifen, in the prevention of breast cancer cells’ 
resistance to tamoxifen. Our results showed that piperine successfully 
increased the efficacy of tamoxifen on the elimination of breast cancer 
cells along with a decrease in P-glycoprotein expression.
We showed that exposure to 1 µM tamoxifen can suppress the growth 
of MCF-7 cells during the early days, but after 6 days, tamoxifen fails 
to suppress the growth of breast cancer cells, as the expression of 
P-glycoprotein increases. This dose-dependent mechanism of increased 
mRNA expression of P-glycoprotein has been shown in human 
hepatocyte primary cells treated with tamoxifen (1, 2, 5, or 5 µM for 
72 h) [14].
Fig. 1: Percentage viability of MCF-7 cells after exposure to 1 µM 
tamoxifen for 12 days
Fig. 2: Levels of P-glycoprotein mRNA expressions (normalized to 
GAPDH as housekeeping gene) in MCF-7 breast cancer cells after 
treatment with 1 µM tamoxifen for up to 12 days
Fig. 3: Percentage of cell viability of MCF-7 breast cancer cells 
after concomitant treatment of tamoxifen 1 µM with piperine 
(12.5, 25, and 50 µM) or with verapamil (50 µM)
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Another study using tamoxifen (10 µM) for 48 h to induce an 
increase in the mRNA expression of P-glycoprotein in human colon 
adenocarcinoma cells showed an increase in that mRNA expression 
associated with the activation of PXR [6]. The differences in the dose 
and exposure duration to tamoxifen treatment used in different studies 
show that these variables are associated to the onset of an increase in 
the mRNA expression of P-glycoprotein.
As mentioned, tamoxifen can activate PXR, which forms a heterodimer 
with the retinoid X receptor and binds the DR-4 response element, 
a functional promoter for the P-glycoprotein gene, resulting in an 
increase in the P-glycoprotein expression [6,15,16-19].
However, some studies have shown that tamoxifen may also act as a 
P-glycoprotein inhibitor [8,17,14]. This is in contrast with our results 
as well as those of other groups. But, it is possible that, at high 
concentrations, tamoxifen inhibits P-glycoprotein as a competitive 
inhibitor of the pump itself. Tamoxifen, which is a P-glycoprotein 
substrate, would compete with other substrates by saturating the 
pump’s binding sites at high enough concentrations and would increase 
the buildup of substrates inside the cell, effectively inhibiting the 
pump’s function [14,20].
In this study, we found that the administration of piperine at various 
concentrations can prevent increased P-glycoprotein mRNA expressions 
in a dose-dependent manner over time. The trend of the curve in Fig. 4 
coincides with the one for the growth curves of MCF-7 cells after the 
administration of piperine at various concentrations as shown in Fig. 3.
Our result is consistent with the finding that piperine at 12.5, 25, 
and 50 µM for 48 h helps overcome the resistance of MCF-7 cells to 
doxorubicin [21].
In addition, piperine at doses between 1 and 250 µM can inhibit the 
P-glycoprotein efflux of digoxin and cyclosporine A in Caco-2 cells with 
IC50 values of 15.5 and 74.1 µM [22].
Conversely, piperine has been shown to exert its effects on the 
P-glycoprotein in a concentration-dependent manner; at small 
concentrations, piperine can inhibit P-glycoprotein, but at 
greater concentrations (50 and 100 µM), piperine can induce 
P-glycoprotein [23].
In our study, the effects of treatment with piperine plus tamoxifen on 
the mRNA expression and cell viability of the MCF-7 cells began being 
apparent after day 6 (when the decreased sensitivity of the cells started 
to develop). This suggests that the administration of piperine from the 
beginning may not be required. However, further studies are required 
to confirm this result.
In this regard, it would be important to detect the beginning of 
the increased P-glycoprotein expression in patients treated with 
tamoxifen, particularly those displaying a decreased response, to 
modify the treatment accordingly. Different methods for detecting 
P-glycoprotein in patients with tumor drug resistance exist, including 
immunocytochemistry or immunohistochemistry, flow cytometry, 
efflux pump tests, and RT-PCR analysis [24].
CONCLUSION
In all, concomitant treatment with piperine and tamoxifen effectively 
prevents the development of breast cancer cells’ resistance against 
tamoxifen, and this effect was probably seen due to the inhibition of 
P-glycoprotein expression.
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